Compound 59c also showed an inverse relationship between KDM5B expression and overall survival from three clinical multiple myeloma trials’ data, suggesting a potential application for KDM5B inhibitors in myeloma therapy. The gene discussed is KDM5B; the disease is plasma cell myeloma.